Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label adjunctive retigabine with antiepileptic monotherapy in adults with partial-onset seizures
NL-OMON34560Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of retigabine in epilepsy and focal-onset epileptic seizures (4 arms), sponsored by GSK. Primary endpoint: Number of seizures. Started Mar 2011; status: active, not recruiting.
02
Drugs
retigabine
03
Conditions
epilepsyfocal-onset epileptic seizures
Beyond the preview
Go deeper on NL-OMON34560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34560.